Exploring GIP Pathways to Combat Obesity & Diabetes to Decrease Comorbidities
- Analysing the GIP pathway to identify opportunities to leverage GIP antagonism for diabetes treatments as a comorbidity of obesity
- Highlighting data showcasing robust effects in type 2 diabetes and insulin sensitivity improvement when GIP is combined with GLP-1 to expand indication treatment opportunities